LYEL · Lyell Immunopharma Inc
United States · RS rating 5 · As of 2026-10-14
| Price | 7.99 USD |
|---|---|
| 1-day change | +6.4% |
| RS rating (overall / 1M / 3M / 12M) | 5 / 7 / 7 / 13 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 22 / 15 / 31 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -210.9% |
| Sales growth Q/Q | -60.0% |
| Distance from 52-week high | +79.3% |
| Market cap (USD) | $550.6M |